350 Years of Merck KGaA, Darmstadt, Germany: Company Looks Ahead to the Future
- 23rd Annual General Meeting in Frankfurt am Main
- A look back at business developments and strategic moves in 2017
- Proposal to raise dividend by € 0.05 to € 1.25 per share
Frankfurt am Main, Germany, April 27, 2018 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, held its 23rd Annual General Meeting today. The company’s 350th anniversary was one of the overriding themes. Stefan Oschmann, CEO and Chairman of the Executive Board, reported to around 1,300 shareholders of Merck KGaA, Darmstadt, Germany, on business developments and strategic moves in 2017 and presented an outlook for the current year.
“2017 was a good year for our company. In a challenging market environment, we met all the financial targets that we had set for ourselves. Our ability to do so despite increasing competition in the Liquid Crystals business and the strength of the euro against the U.S. dollar is thanks to the curiosity, energy and engagement of our nearly 53,000 employees,” said Oschmann. “Of course our shareholders are to benefit from the business results of 2017. Therefore, we propose to the Annual General Meeting an increase in the dividend to € 1.25 per share,” said Oschmann.
As already reported, in 2017 Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion, which corresponds to an increase of 2.0% over the previous year. The strong organic performance of the Healthcare and Life Science business sectors was responsible for this. EBITDA pre, the company’s most important earnings figure, declined by -1.7% to € 4.4 billion. Apart from the difficult foreign exchange environment, the adjustment process in the Liquid Crystals business also contributed to this. Net income rose in 2017 by nearly 60% to a record level of € 2.6 billion. By the end of 2017, Merck KGaA, Darmstadt, Germany, had lowered its net financial debt from the Sigma-Aldrich acquisition by nearly 12% to € 10.1 billion.
In the Healthcare business sector, Merck KGaA, Darmstadt, Germany, achieved a true breakthrough in 2017 with regulatory approval from the U.S. Food and Drug Administration (FDA) for the cancer medicine Bavencio for the treatment of Merkel cell carcinoma. This is a rare and aggressive form of skin cancer. Further approvals for Bavencio in this indication followed, among others in the European Union. Moreover, Bavencio was approved by the FDA also for the treatment of urothelial carcinoma. Apart from Bavencio, the Biopharma business celebrated a second major success in 2017. In August 2017, Merck KGaA, Darmstadt, Germany, received European approval for Mavenclad, a medicine for the treatment of relapsing multiple sclerosis in patients with high disease activity. At the end of 2017, the Group also decided to submit Mavenclad for regulatory approval in the United States this year.
For the Healthcare business sector, 2017 was a year of key strategic moves. In the strategy for its Healthcare business, Merck KGaA, Darmstadt, Germany, has stated its clear objective of becoming a global supplier of innovative specialty products. In parallel to the further development of the pipeline, the company is therefore aligning its business portfolio with this strategy. In August 2017, the Biosimilars business was sold to Fresenius. In September, Merck KGaA, Darmstadt, Germany, then announced plans to examine strategic options for its Consumer Health business. On April 19, 2018, Merck KGaA, Darmstadt, Germany, signed an agreement to divest Consumer Health to Procter & Gamble (P&G) for around € 3.4 billion in cash. The transaction, which is expected to close by the end of the fourth quarter of 2018, is subject to regulatory approvals and satisfaction of certain other customary closing conditions.
The Life Science business sector, which offers products and solutions for laboratories, as well as for biotech and pharmaceutical companies, again generated very solid growth in 2017. This was driven by all business units, especially however by the business with products for large- and small-molecule drug manufacture. In 2017, Merck KGaA, Darmstadt, Germany, received important patents in Life Science. The European Patent Office granted Merck KGaA, Darmstadt, Germany, the patent for its CRISPR technology used in a genomic integration method for eukaryotic cells. In the course of the year, Merck KGaA, Darmstadt, Germany, received further similar patents from the responsible authorities in Australia, Canada and Singapore. In April 2018, the corresponding patent was also granted in China. CRISPR can be used to understand the link between a gene and the function of that gene in a cell. Making these tools available to scientists helps them to design and carry out experiments to elucidate the cause of diseases – one of the most promising technologies in Life Science.
A highlight for Life Science in 2017 was the opening of the new Life Science Center in Burlington, Massachusetts (USA). This enables Merck KGaA, Darmstadt, Germany, to further strengthen its presence in the Greater Boston area, the main biotech hub, and created an attractive working environment, which is highly competitive when it comes to talent and experts. The new facility serves as a regional hub for scientific advances and collaboration with its customers.
In 2017, the Performance Materials business sector, which offers specialty chemicals and high-tech materials, was again the Group’s most profitable business. Nevertheless, Performance Materials faced growing competition in the Liquid Crystals business, particularly in China. By contrast, the other business units of this business sector showed better performance and, in some cases, generated strong organic growth, for instance the semiconductor materials business. In November, Merck KGaA, Darmstadt, Germany, opened a production facility for liquid crystal window modules in Veldhoven, the Netherlands. With an investment of around € 15 million, Merck KGaA, Darmstadt, Germany, continues to build on its expertise as the market and technology leader in liquid crystals for displays by moving into other applications beyond televisions, laptops, smartphones, and tablet PCs. In September, Merck KGaA, Darmstadt, Germany, debuted with its own exhibition stand at the International Motor Show (IAA) in Frankfurt, Europe’s leading automotive exhibition. The focus of the stand was on high-tech materials from Merck KGaA, Darmstadt, Germany, for lighting, antennas, displays and surfaces in the cars of tomorrow.
On September 1, a personnel change took place on the Executive Board, when Kai Beckmann assumed the leadership of the Performance Materials business sector. To strengthen its focus in 2018 even more strongly on the needs of customers and markets, Merck KGaA, Darmstadt, Germany, announced in December 2017 that it will combine the expertise of its Performance Materials business sector in three newly created business units aligned with target markets: Display Solutions, Semiconductor Solutions, and Surface Solutions.
Merck KGaA, Darmstadt, Germany, uses not only financial indicators to measure its performance. The Corporate Responsibility (CR) Report 2017, which was published today, shows what responsible actions mean to the company. The company is focusing its Group-wide sustainability efforts on facilitating access to health among disadvantaged populations in low- and middle-income countries. The Merck KGaA, Darmstadt, Germany, Global Health Institute, which was set up in 2017, is working on infectious diseases and antimicrobial resistance. Furthermore, Merck KGaA, Darmstadt, Germany, wants to boost diversity within the company. The aim is to further women in leadership positions and to maintain the overall proportion of female leaders at a stable level of 30%, while creating an international working environment and achieving a balanced age structure. With the latest CR Report published this year, Merck KGaA, Darmstadt, Germany, is meeting the requirements for a separate, combined non-financial report pursuant to the CSR Directive Implementation Act, which entered into force in 2017. The CR Report also documents progress made in implementing the principles of the United Nations Global Compact.
With a view to 2018, the Group’s CEO Stefan Oschmann warned about the risks posed by Brexit and the reinvigoration of protectionism. Oschmann also explained the forecast given at the company’s Annual Press Conference on March 8, 2018. In 2018, Merck KGaA, Darmstadt, Germany, expects moderate organic growth of Group sales in comparison with 2017. On a currency-adjusted basis, the company forecasts a slight percentage decline in Group EBITDA pre in 2018 compared with 2017. In addition, foreign exchange rates are expected to impact EBITDA pre by approximately -4% to -6% compared with 2017, which will affect all three business sectors. Merck KGaA, Darmstadt, Germany, will provide a quantitative forecast on May 15, 2018 with the publication of its figures for the first quarter of 2018.
Oschmann also gave shareholders his view of the period beyond 2018: “For us, 2018 is a demanding year. We are investing in our future. These efforts will pay off. As of 2019, we should then generate increases again in all key figures: sales, EBITDA pre and EBITDA pre margin. Because then we expect significant earnings from our new medicines. Our aim is for Life Science to continue to grow faster than the market. All this should more than compensate for the trough that we expect in Performance Materials in 2019.”
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.